News | Prostate Cancer | December 22, 2016

Phase II for Development of PSMA-targeted Radionuclide Therapy for Prostate Cancer

Cancer Targeted Technology Commences Second Phase of a $2.3M Contract to Develop an Innovative PSMA-targeted Radionuclide Therapy for Prostate Cancer

 

prostate, CT scan

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, announced that the National Cancer Institute exercised the $2M Phase II option of a Small Business Innovation Research (SBIR) Phase I/II fast-track $2.3M contract to develop a new agent to treat metastatic prostate cancer. The contract develops a promising unique radiotherapeutic drug, CTT1403, that targets Prostate-Specific Membrane Antigen (PSMA). PSMA is over-expressed on prostate cancer and expression increases as the cancer metastasizes and becomes castrate-resistant. CTT’s unique phosphoramidate-based agents, bind irreversibly to PSMA and unlike other agents targeting PSMA, this distinctive mode of binding enhances uptake and internalization by tumor cells leading to increased accumulation of the therapeutic payload and improved efficacy.

In the Phase I $300K portion of the contract, conducted earlier in 2016, CTT successfully synthesized, tested and identified its lead drug, CTT1403. In addition to the PSMA targeting core, CTT1403 incorporates a chemical motif to increase circulation time, increase tumor uptake and decrease any binding to normal tissues. CTT1403, labeled with lutetium-177, demonstrated excellent circulation times in animal studies and cured 75% of mice implanted with human prostate tumors. CTT is working with Carolyn Anderson, M.D., professor of medicine, at University of Pittsburgh, to evaluate CTT1403 in mouse models of prostate cancer.

Anderson commented: "We are excited to continue our collaboration with CTT. The data from the first phase of the contract are promising, and we look forward to furthering this investigation to translate CTT1403 into human studies.”

The Phase II $2M portion advances CTT1403 into Investigational New Drug (IND) enabling studies, including manufacturing, additional pharmacology and safety assessments. These IND studies will support the initial clinical trial in metastatic prostate cancer. CTT’s strategic plan to identify, target, treat and monitor metastatic prostate cancer, employs CTT1403 as a companion therapeutic agent to CTT’s diagnostic Positron Emission Tomography (PET) agent, CTT1057, that commenced clinical trials in November 2016 to image metastatic sites in patients with prostate cancer.

“We have rationally designed CTT1403 to maximize tumor uptake, while minimizing side effects, and the drug is demonstrating exceptional targeting to prostate tumors in animal models,” stated Beatrice Langton-Webster, Ph.D., CEO of CTT and Principal Investigator on the contract. “We were very excited to see substantial increases in survival times in mice implanted with human prostate tumors. CTT1403 holds great promise as a treatment that will result in meaningful increases in life expectancy for men suffering from prostate cancer.”

For more information: www.cancertargetedtechnology.com/

Related Content

Medrad Intego PET Infusion System, recall
News | Nuclear Imaging | January 12, 2017
January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source Admini
Technology | Quality Assurance (QA) | January 10, 2017
January 10, 2017 — Mobius Medical Systems LP announced in December that DoseLab, the complete TG-142 solution, now fu
News | Radiopharmaceuticals and Tracers | January 06, 2017
New research demonstrates that a novel imaging agent can quickly and accurately detect metastasis of prostate cancer,...
Varian, radiotherapy, online educational resource, cancer
News | Radiation Therapy | January 05, 2017
January 5, 2017 — Varian Medical Systems recently announced the launch of a new website for the exchange of clinical
Sponsored Content | Videos | Radiation Oncology | January 05, 2017
Join Chris Toth, president, Oncology Systems Americas, for a look at Varian’s new product introductions and major ini
iCAD, IORT boost, Xoft Axxent Electronic Brachytherapy System, intraoperative radiation therapy, whole breast radiation, early-stage breast cancer, SABCS 2016
News | Brachytherapy Systems | January 05, 2017
iCAD Inc. announced that researchers presented updated data on the use of intraoperative radiation therapy (IORT) with...
metastatic colorectal cancer, mCRC, Sirtex, NCCN guidelines, Y-90 microspheres
News | Radiation Therapy | January 03, 2017
Sirtex Medical Limited announced in December that SIR-Spheres Y-90 resin microspheres have been included as a Category...
radiation therapy complications with implant reconstruction, autologous reconstruction
News | Radiation Therapy | January 02, 2017
January 2, 2017 — Radiotherapy increased complications and impaired patient-reported satisfaction with reconstructed
SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals
News | December 28, 2016
December 28, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has developed United States Pharmac
News | Radiation Therapy | December 23, 2016
A University of Rochester Medical Center study shows that when tumors are treated with radiotherapy, the benefits can...
Overlay Init